Adcock Ingram Holdings (JSE:AIP) Short Interest

View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Adcock Ingram Holdings's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Adcock Ingram Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adcock Ingram Holdings's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adcock Ingram Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Adcock Ingram Holdings's Short Interest falls into.

Adcock Ingram Holdings (JSE:AIP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682

Website

https://www.adcock.com

Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.